The company said total sales for Q3 2025 were $17,276 million, up 4% from the year-earlier quarter (3% excluding foreign exchange), and that GAAP EPS was $2.32 and non-GAAP EPS was $2.58.

1. 01

   The company said total sales for Q3 2025 were $17,276 million, up 4% from the year-earlier quarter (3% excluding foreign exchange), and that GAAP EPS was $2.32 and non-GAAP EPS was $2.58.

2. 02

   The company said KEYTRUDA sales rose 10% to $8,142 million in Q3, and WINREVAIR sales grew 141% to $360 million, while GARDASIL/GARDASIL 9 sales fell 24% to $1,749 million.

3. 03

   Merck said its GAAP and non-GAAP EPS for Q3 2025 included a charge of $0.10 per share for the milestone payment to LaNova for the technology transfer for MK-MK-2010. It said the year-earlier quarter included a net charge of $0.79 per share for the EyeBio, Curon and Daiichi Sankyo transactions.

4. 04

   The company set its full-year 2025 sales outlook at $64.5 billion to $65.0 billion (previously $64.3 billion to $65.3 billion) and its non-GAAP EPS outlook at $8.93 to $8.98 (previously $8.87 to $8.97).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.